Metalloproteinases and their natural inhibitors in inflammation and immunity

Nature Reviews Immunology

Volumn 13, Issue 9, 2013, Pages 649-665

  Khokha, Rama ^a   Murthy, Aditya ^a   Weiss, Ashley ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; CLOSTRIDIOPEPTIDASE A; COMPLEMENTARY DNA; ERYTHROID POTENTIATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; MEPRIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

AUTOIMMUNE DISEASE; CELL INTERACTION; EXTRACELLULAR MATRIX; HEMATOPOIESIS; IMMUNITY; IMMUNOCOMPETENT CELL; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84883143934     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3499     Document Type: Review

References (160)

1. Gross, J. & Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc. Natl Acad. Sci. USA 48, 1014-1022 (1962).
2. Gasson, J. C. et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature 315, 768-771 (1985).
3. Docherty, A. J. et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318, 66-69 (1985).
4. Nagase, H., Visse, R. & Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69, 562-573 (2006).
5. Visse, R. & Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 92, 827-839 (2003).
6. Klein, T. & Bischoff, R. Active metalloproteases of the a disintegrin and metalloprotease (ADAM) family: biological function and structure. J. Proteome Res. 10, 17-33 (2011).
7. McQuibban, G. A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202-1206 (2000).
8. Van den Steen, P. E., Proost, P., Wuyts, A., Van Damme, J. & Opdenakker, G. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO and leaves RANTES and MCP-2 intact. Blood 96, 2673-2681 (2000).
9. Clark, I. M., Swingler, T. E., Sampieri, C. L. & Edwards, D. R. The regulation of matrix metalloproteinases and their inhibitors. Int. J. Biochem. Cell Biol. 40, 1362-1378 (2008).
10. Chernov, A. V. & Strongin, A. Y. Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. Biomol. Concepts 2, 135-147 (2011).
11. Fata, J. E., Ho, A. T., Leco, K. J., Moorehead, R. A. & Khokha, R. Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors. Cell. Mol. Life Sci. 57, 77-95 (2000).
12. Nuttall, R. K. et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett. 563, 129-134 (2004).
13. Murthy, A. et al. Stromal TIMP3 regulates liver lymphocyte populations and provides protection against Th1 T cell-driven autoimmune hepatitis. J. Immunol. 188, 2876-2883 (2012).
14. Masure, S., Proost, P., Van Damme, J. & Opdenakker, G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 198, 391-398 (1991).
15. Opdenakker, G. et al. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leukoc. Biol. 69, 851-859 (2001).
16. Bar-Or, A. et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 126, 2738-2749 (2003).
17. Meissner, F., Scheltema, R. A., Mollenkopf, H. J. & Mann, M. Direct proteomic quantification of the secretome of activated immune cells. Science 340, 475-478 (2013).
18. Tocchi, A. & Parks, W. C. Functional interactions between matrix metalloproteinases and glycosaminoglycans. FEBS J. 280, 2332-2341 (2013).
19. Amour, A. et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473, 275-279 (2000).
20. Murphy, G. et al. Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochem. Soc. Symp. 65-80 (2003).
21. Murthy, A. et al. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice. J. Clin. Invest. 120, 2731-2744 (2010).
22. Le Gall, S. M. et al. ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site. J. Cell Sci. 123, 3913-3922 (2010).
23. Xu, P., Liu, J., Sakaki-Yumoto, M. & Derynck, R. TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association. Sci Signal 5, ra34 (2012).
24. Willems, S. H. et al. Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem. J. 428, 439-450 (2010).
25. McIlwain, D. R. et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science 335, 229-232 (2012).
26. Adrain, C., Zettl, M., Christova, Y., Taylor, N. & Freeman, M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science 335, 225-228 (2012).
27. Scilabra, S. D. et al. Differential regulation of extracellular tissue inhibitor of metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein receptor-related protein 1. J. Biol. Chem. 288, 332-342 (2013).
28. Troeberg, L. et al. Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J. 22, 3515-3524 (2008).
29. Black, R. A. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-from cells. Nature 385, 729-733 (1997).
30. Moss, M. L. et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor. Nature 385, 733-736 (1997).
31. Grell, M. et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83, 793-802 (1995).
32. Peschon, J. J. et al. An essential role for ectodomain shedding in mammalian development. Science 282, 1281-1284 (1998).
33. Bell, J. H., Herrera, A. H., Li, Y. & Walcheck, B. Role of ADAM17 in the ectodomain shedding of TNF and its receptors by neutrophils and macrophages. J. Leukoc. Biol. 82, 173-176 (2007).
34. Horiuchi, K. et al. Cutting edge: TNF-converting enzyme (TACE/ADAM17) inactivation in mouse myeloid cells prevents lethality from endotoxin shock. J. Immunol. 179, 2686-2689 (2007).
35. Smookler, D. S. et al. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J. Immunol. 176, 721-725 (2006).
36. Mohammed, F. F. et al. Abnormal TNF activity in Timp3 mice leads to chronic hepatic inflammation and failure of liver regeneration. Nature Genet. 36, 969-977 (2004).
37. Guinea-Viniegra, J. et al. TNF shedding and epidermal inflammation are controlled by Jun proteins. Genes Dev. 23, 2663-2674 (2009).
38. Gregory, A. P. et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508-511 (2012).
39. Young, J. et al. Lymphotoxin heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 51, 78-86 (2010).
40. Summers deLuca, L. & Gommerman, J. L. Fine-tuning of dendritic cell biology by the TNF superfamily. Nature Rev. Immunol. 12, 339-351 (2012).
41. Godefroy, E. et al. Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory TH2 cells via an IL-12-and OX40L-dependent pathway. Cancer Cell 19, 333-346 (2011).
42. Briso, E. M., Dienz, O. & Rincon, M. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J. Immunol. 180, 7102-7106 (2008).
43. Chalaris, A. et al. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by secretase. Biochim. Biophys. Acta 1803, 234-245 (2010).
44. Garbers, C. et al. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J. Biol. Chem. 286, 14804-14811 (2011).
45. IL6R Genetics Consortium and Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205-1213 (2012).
46. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214-1224 (2012).
47. Jones, S. A., Scheller, J. & Rose-John, S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121, 3375-3383 (2011).
48. Chen, Q. et al. Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nature Immunol. 7, 1299-1308 (2006).
49. Chen, Q. et al. Central role of IL-6 receptor signal-transducing chain gp130 in activation of L-selectin adhesion by fever-range thermal stress. Immunity 20, 59-70 (2004).
50. Yan, F. et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J. Clin. Invest. 121, 2242-2253 (2011).
51. Yan, F. et al. Epidermal growth factor receptor activation protects gastric epithelial cells from Helicobacter pylori-induced apoptosis. Gastroenterology 136, 1297-1307, e1-3 (2009).
52. Sahin, U. et al. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J. Cell Biol. 164, 769-779 (2004).
53. Brandl, K. et al. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc. Natl Acad. Sci. USA 107, 19967-19972 (2010).
54. Chalaris, A. et al. Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J. Exp. Med. 207, 1617-1624 (2010).
55. Bauer, B. et al. The Helicobacter pylori virulence effector CagA abrogates human defensin 3 expression via inactivation of EGFR signaling. Cell Host Microbe 11, 576-586 (2012).
56. Saha, A., Backert, S., Hammond, C. E., Gooz, M. & Smolka, A. J. Helicobacter pylori CagL activates ADAM17 to induce repression of the gastric H, K-ATPase subunit. Gastroenterology 139, 239-248 (2010).
57. Franzke, C. W. et al. Epidermal ADAM17 maintains the skin barrier by regulating EGFR ligand-dependent terminal keratinocyte differentiation. J. Exp. Med. 209, 1105-1119 (2012).
58. Monticelli, L. A. et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nature Immunol. 12, 1045-1054 (2011).
59. Stephenson, N. L. & Avis, J. M. Direct observation of proteolytic cleavage at the S2 site upon forced unfolding of the Notch negative regulatory region. Proc. Natl Acad. Sci. USA 109, E2757-E2765 (2012).
60. van Tetering, G. et al. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J. Biol. Chem. 284, 31018-31027 (2009).
61. Bozkulak, E. C. & Weinmaster, G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol. Cell. Biol. 29, 5679-5695 (2009).
62. Tian, L. et al. ADAM10 is essential for proteolytic activation of Notch during thymocyte development. Int. Immunol. 20, 1181-1187 (2008).
63. Brou, C. et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 5, 207-216 (2000).
64. Gibb, D. R. et al. ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo. J. Exp. Med. 207, 623-635 (2010).
65. Guinea-Viniegra, J. et al. Differentiation-induced skin cancer suppression by FOS, 53, and TACE/ADAM17. J. Clin. Invest. 122, 2898-2910 (2012).
66. Blaydon, D. C. et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N. Engl. J. Med. 365, 1502-1508 (2011).
67. Dumortier, A. et al. Atopic dermatitis-like disease and associated lethal myeloproliferative disorder arise from loss of Notch signaling in the murine skin. PLoS ONE 5, e9258 (2010).
68. Demehri, S. et al. Notch-deficient skin induces a lethal systemic B-lymphoproliferative disorder by secreting TSLP, a sentinel for epidermal integrity. PLoS Biol. 6, e123 (2008).
69. Weber, S. et al. The disintegrin/metalloproteinase Adam10 is essential for epidermal integrity and Notch-mediated signaling. Development 138, 495-505 (2011).
70. Murthy, A. et al. Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity 36, 105-119 (2012).
71. Groot, A. J. et al. Epidermal ADAM17 is dispensable for Notch activation. J. Invest. Dermatol. http://dx.doi. org/10.1038/jid.2013.162 (2013).
72. Broder, C. & Becker-Pauly, C. The metalloproteases meprin and meprin: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis. Biochem. J. 450, 253-264 (2013).
73. Jefferson, T. et al. The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin and ADAM10. Cell. Mol. Life Sci. 70, 309-33 (2012).
74. Strowig, T., Henao-Mejia, J., Elinav, E. & Flavell, R. Inflammasomes in health and disease. Nature 481, 278-286 (2012).
75. Herzog, C. et al. Meprin A and meprin generate biologically functional IL-1 from pro-IL-1. Biochem. Biophys. Res. Commun. 379, 904-908 (2009).
76. Banerjee, S. & Bond, J. S. Prointerleukin-18 is activated by meprin in vitro and in vivo in intestinal inflammation. J. Biol. Chem. 283, 31371-31377 (2008).
77. Vazeille, E. et al. Role of meprins to protect ileal mucosa of Crohn's disease patients from colonization by adherent-invasive E. coli. PLoS ONE 6, e21199 (2011).
78. Li, Q., Park, P. W., Wilson, C. L. & Parks, W. C. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 111, 635-646 (2002).
79. Tester, A. M. et al. LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity. PLoS ONE 2, e312 (2007).
80. Song, J., Wu, C., Zhang, X. & Sorokin, L. M. In Vivo processing of CXCL5 (LIX) by matrix metalloproteinase (MMP)-2 and MMP-9 promotes early neutrophil recruitment in IL-1?-induced peritonitis. J. Immunol. 190, 401-410 (2013).
81. Geurts, N. et al. Meprins process matrix metalloproteinase-9 (MMP-9)/gelatinase B and enhance the activation kinetics by MMP-3. FEBS Lett. 586, 4264-4269 (2012).
82. Kim, K. H. et al. Tissue inhibitor of metalloproteinase-1 deficiency amplifies acute lung injury in bleomycin-exposed mice. Am. J. Respir. Cell. Mol. Biol. 33, 271-279 (2005).
83. Gill, S. E. et al. Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am. J. Pathol. 176, 64-73 (2010).
84. Smalley, D. M. & Ley, K. L-selectin: mechanisms and physiological significance of ectodomain cleavage. J. Cell. Mol. Med. 9, 255-266 (2005).
85. Long, C., Hosseinkhani, M. R., Wang, Y. Sriramarao, P. & Walcheck, B. ADAM17 activation in circulating neutrophils following bacterial challenge impairs their recruitment. J. Leukoc. Biol. 92, 667-672 (2012).
86. Tang, J. et al. Adam17-dependent shedding limits early neutrophil influx but does not alter early monocyte recruitment to inflammatory sites. Blood 118, 786-794 (2011).
87. Vlahos, R., Wark, P. A., Anderson, G. P. & Bozinovski, S. Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD. PLoS ONE 7, e33277 (2012).
88. Baines, K. J., Simpson, J. L. & Gibson, P. G. Innate immune responses are increased in chronic obstructive pulmonary disease. PLoS ONE 6, e18426 (2011).
89. Castano, R. et al. Matrix metalloproteinase-9 increases in the sputum from allergic occupational asthma patients after specific inhalation challenge. Int. Arch. Allergy Immunol. 160, 161-164 (2012).
90. Moncada-Pazos, A. et al. ADAMTS-12 metalloprotease is necessary for normal inflammatory response. J. Biol. Chem. 287, 39554-39563 (2012).
91. Wang, Y. et al. ADAM17 cleaves CD16b (Fc?RIIIb) in human neutrophils. Biochim. Biophys. Acta 1833, 680-685 (2013).
92. Hojilla, C. V., Jackson, H. W. & Khokha, R. TIMP3 regulates mammary epithelial apoptosis with immune cell recruitment through differential TNF dependence. PLoS ONE 6, e26718 (2011).
93. Huang, W. C., Sala-Newby, G. B., Susana, A., Johnson, J. L. & Newby, A. C. Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-?B. PLoS ONE 7, e42507 (2012).
94. Shimizu-Hirota, R. et al. MT1-MMP regulates the PI3K?•Mi-2/NuRD- dependent control of macrophage immune function. Genes Dev. 26, 395-413 (2012).
95. Dean, R. A. et al. Macrophage-specific metalloelastase (MMP-12) truncates and inactivates ELR+ CXC chemokines and generates CCL2,-7,-8, and-13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood 112, 3455-3464 (2008).
96. Andersson, C. X. et al. Shedding and ?-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43. Biochem. J. 387, 377-384 (2005).
97. Carey, B. W., Kim, D. Y. & Kovacs, D. M. Presenilin-secretase and secretase-like peptidases cleave human MHC Class I proteins. Biochem. J. 401, 121-127 (2007).
98. Mysliwiec, J., Oklota, M., Nikolajuk, A., Waligorski, D. & Gorska, M. Serum CD40/CD40L system in Graves' disease and Hashimoto's thyroiditis related to soluble Fas, FasL and humoral markers of autoimmune response. Immunol. Invest. 36, 247-257 (2007).
99. McGinn, O. J. et al. Modulation of integrin 41 by ADAM28 promotes lymphocyte adhesion and transendothelial migration. Cell Biol. Int. 35, 1043-1053 (2011).
100. Yang, S., Liu, F., Wang, Q. J., Rosenberg, S. A. & Morgan, R. A. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLoS ONE 6, e22560 (2011).
101. Groh, V., Wu, J., Yee, C. & Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419, 734-738 (2002).
102. Kaiser, B. K. et al. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447, 482-486 (2007).
103. Boutet, P. et al. Cutting edge: the metalloproteinase ADAM17/TNF-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J. Immunol. 182, 49-53 (2009).
104. Cardellini, M. et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes 58, 2396-2401 (2009).
105. Casagrande, V. et al. Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 32, 74-81 (2012).
106. Koskivirta, I. et al. Tissue inhibitor of metalloproteinases 4 (TIMP4) is involved in inflammatory processes of human cardiovascular pathology. Histochem. Cell Biol. 126, 335-342 (2006).
107. Korematsu, S. et al. Cell distribution differences of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in patients with Kawasaki disease. Pediatr. Infect. Dis. J. 31, 973-974 (2012).
108. Shao, Q. et al. Regulation of Th1/Th2 polarization by tissue inhibitor of metalloproteinase-3 via modulating dendritic cells. Blood 119, 4636-4644 (2012).
109. Pozgan, U. et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol. Chem. 391, 571-579 (2010).
110. Toft-Hansen, H., Nuttall, R. K., Edwards, D. R. & Owens, T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J. Immunol. 173, 5209-5218 (2004).
111. Piccard, H., Van den Steen, P. E. & Opdenakker, G. Hemopexin domains as multifunctional liganding modules in matrix metalloproteinases and other proteins. J. Leukoc. Biol. 81, 870-892 (2007).
112. Rossi, L., Ergen, A. V. & Goodell, M. A. TIMP-1 deficiency subverts cell-cycle dynamics in murine long-term HSCs. Blood 117, 6479-6488 (2011).
113. Nakajima, H. et al. TIMP-3 recruits quiescent hematopoietic stem cells into active cell cycle and expands multipotent progenitor pool. Blood 116, 4474-4482 (2010).
114. Shen, Y. et al. Tissue inhibitor of metalloproteinase-3 (TIMP-3) regulates hematopoiesis and bone formation in vivo. PLoS ONE 5, e13086 (2010).
115. Ota, I., Li, X. Y., Hu, Y. & Weiss, S. J. Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1. Proc. Natl Acad. Sci. USA 106, 20318-20323 (2009).
116. Rowlands, D. J. et al. Activation of TNFR1 ectodomain shedding by mitochondrial Ca2+ determines the severity of inflammation in mouse lung microvessels. J. Clin. Invest. 121, 1986-1999 (2011).
117. Ahonen, M. et al. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 22, 2121-2134 (2003).
118. Inoshima, I. et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nature Med. 17, 1310-1314 (2011).
119. Ganz, T. Defensins: antimicrobial peptides of innate immunity. Nature Rev. Immunol. 3, 710-720 (2003).
120. Pugin, J. et al. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am. J. Respir. Cell. Mol. Biol. 20, 458-464 (1999).
121. Qu, P., Yan, C. & Du, H. Matrix metalloproteinase 12 overexpression in myeloid lineage cells plays a key role in modulating myelopoiesis, immune suppression, and lung tumorigenesis. Blood 117, 4476-4489 (2011).
122. Kim, Y. H., Kwon, H. J. & Kim, D. S. Matrix metalloproteinase 9 (MMP-9)-dependent processing of ig-h3 protein regulates cell migration, invasion, and adhesion. J. Biol. Chem. 287, 38957-38969 (2012).
123. Schonbeck, U. et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med. 189, 843-853 (1999).
124. Soumyarani, V. S. & Jayakumari, N. Oxidatively modified high density lipoprotein promotes inflammatory response in human monocytes-macrophages by enhanced production of ROS, TNF, MMP-9, and MMP-2. Mol. Cell Biochem. 366, 277-285 (2012).
125. Uzui, H. et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 106, 3024-3030 (2002).
126. Fu, X., Kassim, S. Y., Parks, W. C. & Heinecke, J. W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 276, 41279-41287 (2001).
127. Rajagopalan, S., Meng, X. P., Ramasamy, S., Harrison, D. G. & Galis, Z. S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98, 2572-2579 (1996).
128. Fabunmi, R. P., Sukhova, G. K., Sugiyama, S. & Libby, P. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ. Res. 83, 270-278 (1998).
129. Okada, Y. et al. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett. 229, 157-160 (1988).
130. Fanjul-Fernandez, M. et al. Matrix metalloproteinase mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J. Biol. Chem. 288, 14647-14656 (2013).
131. Foley, C. J. et al. Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. Oncogene http://dx.doi.org/10.1038/onc.2013.157 (2013).
132. Westermann, D. et al. Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation 124, 2082-2093 (2011).
133. Wang, M. et al. Matrix metalloproteinase deficiencies affect contact hypersensitivity: stromelysin-1 deficiency prevents the response and gelatinase B deficiency prolongs the response. Proc. Natl Acad. Sci. USA 96, 6885-6889 (1999).
134. Nerusu, K. C. et al. Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. Exp. Mol. Pathol. 83, 169-176 (2007).
135. Salzman, N. H. et al. Enteric defensins are essential regulators of intestinal microbial ecology. Nature Immunol. 11, 76-83 (2010).
136. Gutierrez-Fernandez, A. et al. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP-8). FASEB J. 21, 2580-2591 (2007).
137. Bradley, L. M., Douglass, M. F., Chatterjee, D., Akira, S. & Baaten, B. J. Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling. PLoS Pathog. 8, e1002641 (2012).
138. Awla, D. et al. Neutrophil-derived matrix metalloproteinase-9 is a potent activator of trypsinogen in acinar cells in acute pancreatitis. J. Leukoc. Biol. 91, 711-719 (2012).
139. Hong, J. S. et al. Dual protective mechanisms of matrix metalloproteinases 2 and 9 in immune defense against Streptococcus pneumoniae. J. Immunol. 186, 6427-6436 (2011).
140. Lagente, V., Le Quement, C. & Boichot, E. Macrophage metalloelastase (MMP-12) as a target for inflammatory respiratory diseases. Expert Opin. Ther. Targets 13, 287-295 (2009).
141. Li, J. et al. Macrophage metalloelastase (MMP-12) deficiency mitigates retinal inflammation and pathological angiogenesis in ischemic retinopathy. PLoS ONE 7, e52699 (2012).
142. Sen, A. I., Shiomi, T., Okada, Y. & D'Armiento, J. M. Deficiency of matrix metalloproteinase-13 increases inflammation after acute lung injury. Exp. Lung Res. 36, 615-624 (2010).
143. Holmbeck, K. et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99, 81-92 (1999).
144. Beck, I. M. et al. MMP19 is essential for T cell development and T cell-mediated cutaneous immune responses. PLoS ONE 3, e2343 (2008).
145. Yu, G. et al. Matrix metalloproteinase-19 is a key regulator of lung fibrosis in mice and humans. Am. J. Respir. Crit. Care Med. 186, 752-762 (2012).
146. Pendas, A. M. et al. Diet-induced obesity and reduced skin cancer susceptibility in matrix metalloproteinase 19-deficient mice. Mol. Cell. Biol. 24, 5304-5313 (2004).
147. Folgueras, A. R. et al. Metalloproteinase MT5-MMP is an essential modulator of neuro-immune interactions in thermal pain stimulation. Proc. Natl Acad. Sci. USA 106, 16451-16456 (2009).
148. Manicone, A. M. et al. Epilysin (MMP-28) restrains early macrophage recruitment in Pseudomonas aeruginosa pneumonia. J. Immunol. 182, 3866-3876 (2009).
149. Knolle, M. D. & Owen, C. A. ADAM8: a new therapeutic target for asthma. Expert Opin. Ther. Targets 13, 523-540 (2009).
150. Hartmann, D. et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for secretase activity in fibroblasts. Hum. Mol. Genet. 11, 2615-2624 (2002).
151. Canault, M., Certel, K., Schatzberg, D., Wagner, D. D. & Hynes, R. O. The lack of ADAM17 activity during embryonic development causes hemorrhage and impairs vessel formation. PLoS ONE 5, e13433 (2010).
152. Horiuchi, K. et al. Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis and increased granulopoiesis via dysregulation of IL-17 and G-CSF. J. Immunol. 182, 2093-2101 (2009).
153. Zaar, A., Eisenreich, W., Bacher, A. & Fuchs, G. A novel pathway of aerobic benzoate catabolism in the bacteria Azoarcus evansii and Bacillus stearothermophilus. J. Biol. Chem. 276, 24997-25004 (2001).
154. Ji, Y. H., Matsushita, M., Okada, H., Fujita, T. & Kawakami, M. The C4 and C2 but not C1 components of complement are responsible for the complement activation triggered by the Ra-reactive factor. J. Immunol. 141, 4271-4275 (1988).
155. Menghini, R. et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136, 663-672.e4 (2009).
156. Koskivirta, I. et al. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J. Biol. Chem. 285, 24487-24493 (2010).
157. Banerjee, S. et al. MEP1A allele for meprin A metalloprotease is a susceptibility gene for inflammatory bowel disease. Mucosal Immunol. 2, 220-231 (2009).
158. Yura, R. E., Bradley, S. G., Ramesh, G., Reeves, W. B. & Bond, J. S. Meprin A metalloproteases enhance renal damage and bladder inflammation after LPS challenge. Am. J. Physiol. Renal Physiol. 296, F135-144 (2009).
159. Crisman, J. M., Zhang, B., Norman, L. P. & Bond, J. S. Deletion of the mouse meprin metalloprotease gene diminishes the ability of leukocytes to disseminate through extracellular matrix. J. Immunol. 172, 4510-4519 (2004).
160. Banerjee, S. et al. Balance of meprin A and B in mice affects the progression of experimental inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G273-282 (2011).